Risk Factors, Stroke Prevention Treatments, and Prevalence of Cerebral Microbleeds in the Framingham Heart Study | Zendy

José R. Romero | Zendy; Sarah R. Preis | Zendy; Alexa S. Beiser | Zendy; Charles DeCarli | Zendy; Anand Viswanathan | Zendy; Sergi MartínezRamírez | Zendy; Carlos S. Kase | Zendy; Philip A. Wolf | Zendy; Sudha Seshadri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk Factors, Stroke Prevention Treatments, and Prevalence of Cerebral Microbleeds in the Framingham Heart Study

Author(s) -

José R. Romero,

Sarah R. Preis,

Alexa S. Beiser,

Charles DeCarli,

Anand Viswanathan,

Sergi MartínezRamírez,

Carlos S. Kase,

Philip A. Wolf,

Sudha Seshadri

Publication year - 2014

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.114.004130

Subject(s) - medicine , framingham heart study , cerebral amyloid angiopathy , stroke (engine) , statin , risk factor , framingham risk score , odds ratio , apolipoprotein e , cross sectional study , cardiology , dementia , pathology , disease , mechanical engineering , engineering

Cerebral microbleeds (CMBs) are associated with increased risk of stroke and poor cognition. Vascular risk factors and medications used for stroke prevention may increase the risk of CMB. We examined the prevalence of CMB and the association of these risk factors with CMB, postulating that risk factors for cerebral amyloid angiopathy would be associated with lobar CMB and markers of hypertensive vasculopathy with deep CMB.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research